Identity and synonyms
Alias resolution required before any future CMS replacement.
Synonyms: CJC-1295 without DAC · CJC sin DAC
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: GHRH analogue identity family
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Commercial identity or variant awaiting clarification.
Mechanism
Intended GHRH-receptor stimulation; confirm exact molecule rather than relying on vendor nickname.
Evidence and critical reading
Reported scientific and empirical uses
GH/IGF hormonal axis
Combination with ipamorelin is presented as a two-receptor strategy. Plausibility of greater GH secretion does not establish clinical combination benefit.
Human evidence
The long-acting CJC-1295 trials cannot be assigned to this “without DAC” identity. Exact-product clinical outcomes remain unresolved.
Preclinical evidence
Shared pathway does not establish equal kinetics or safety.
Critical reading and limitations
One handbook contains discordant units and another a commercial tiered table. Neither establishes a dosing standard. The guide displays sources and uncertainty; conflicting quantities are neither normalized nor turned into recommendations.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Combination endocrine effects are plausible but not quantified; formal contraindications and interactions are unestablished.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
modified GRF 1-29 · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
Page contains discordant fixed and weight-based amounts; no validated quantity is generated. · manual02 · Page 83
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID16352683
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA.
October 16, 2026
- R10
- R11
- manual02
peptide-protocols-volume-one.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026